Literature DB >> 17204473

Viral infections activate types I and III interferon genes through a common mechanism.

Kazuhide Onoguchi1, Mitsutoshi Yoneyama, Azumi Takemura, Shizuo Akira, Tadatsugu Taniguchi, Hideo Namiki, Takashi Fujita.   

Abstract

Viral infections trigger innate immune responses, including the production of type I interferons (IFN-alpha and -beta) and other proinflammatory cytokines. Novel antiviral cytokines IFN-lambda1, IFN-lambda2, and IFN-lambda3 are classified as type III IFNs and have evolved independently of type I IFNs. Type III IFN genes are regulated at the level of transcription and induced by viral infection. Although the regulatory mechanism of type I IFNs is well elucidated, the expression mechanism of IFN-lambdas is not well understood. Here, we analyzed the mechanism by which IFN-lambda gene expression is induced by viral infections. Loss- and gain-of-function experiments revealed the involvement of RIG-I (retinoic acid-inducible gene I), IPS-1, TBK1, and interferon regulatory factor-3, key regulators of the virus-induced activation of type I IFN genes. Consistent with this, a search for the cis-regulatory element of the human ifnlambda1 revealed a cluster of interferon regulatory factor-binding sites and a NF-kappaB-binding site. Functional analysis demonstrated that all of these sites are essential for gene activation by the virus. These results strongly suggest that types I and III IFN genes are regulated by a common mechanism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17204473     DOI: 10.1074/jbc.M608618200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  147 in total

Review 1.  Induction and evasion of innate antiviral responses by hepatitis C virus.

Authors:  Stanley M Lemon
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  Type III IFNs in pteropid bats: differential expression patterns provide evidence for distinct roles in antiviral immunity.

Authors:  Peng Zhou; Chris Cowled; Shawn Todd; Gary Crameri; Elena R Virtue; Glenn A Marsh; Reuben Klein; Zhengli Shi; Lin-Fa Wang; Michelle L Baker
Journal:  J Immunol       Date:  2011-01-28       Impact factor: 5.422

3.  IFN-lambda determines the intestinal epithelial antiviral host defense.

Authors:  Johanna Pott; Tanel Mahlakõiv; Markus Mordstein; Claudia U Duerr; Thomas Michiels; Silvia Stockinger; Peter Staeheli; Mathias W Hornef
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 4.  Impact of aging on dendritic cell functions in humans.

Authors:  Anshu Agrawal; Sudhir Gupta
Journal:  Ageing Res Rev       Date:  2010-07-07       Impact factor: 10.895

Review 5.  Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus.

Authors:  Nicole E Pagliaccetti; Michael D Robek
Journal:  J Interferon Cytokine Res       Date:  2010-08       Impact factor: 2.607

6.  Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling.

Authors:  Barbara Kroczynska; Sonali Joshi; Elizabeth A Eklund; Amit Verma; Sergei V Kotenko; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

Review 7.  Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history.

Authors:  Patricia Fitzgerald-Bocarsly; Jihong Dai; Sukhwinder Singh
Journal:  Cytokine Growth Factor Rev       Date:  2008-01-11       Impact factor: 7.638

8.  The DNA damage response induces IFN.

Authors:  Sabrina Brzostek-Racine; Chris Gordon; Sarah Van Scoy; Nancy C Reich
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

9.  The role of transposable elements in the regulation of IFN-lambda1 gene expression.

Authors:  Scott J P Thomson; Fui G Goh; Helen Banks; Thomas Krausgruber; Sergei V Kotenko; Brian M J Foxwell; Irina A Udalova
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-01       Impact factor: 11.205

10.  Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine.

Authors:  Oscar Antonio Ortega-Rivera; J Luis Quintanar; Susana Del Toro-Arreola; Ángel G Alpuche-Solis; Mayra J Esparza-Araiza; Eva Salinas
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.